Alexion Pharmaceuticals to pay $21.4 million to settle FCPA violations

1971
SHARE
Alexion Pharmaceuticals

Alexion Pharmaceuticals agreed to pay $21.4 million to settle a complaint by the Securities and Exchange Commission (SEC) alleging that it violated the provisions of the Foreign Corrupt Practices Act (FCPA).

According to the Commission, the company’s FCPA violations were in connection with the business practices of its subsidiaries in Turkey, Russia, Colombia, and Brazil.

Allegations against Alexion Pharmaceuticals

The SEC alleged that Alexion Pharmaceuticals’ subsidiaries in the four countries did not comply with the internal accounting controls and recordkeeping provisions of the FCPA.

From 2010 to 2015, Alexion Turkey allegedly made improper payments to Turkish government officials to obtain patient prescription approvals and favorable regulatory treatment for its primary drug Soliris.

From 2011 to 2015, Alexion Russia also allegedly made improper payments to Russian government health care officials to secure favorable treatment and influence budget allocations to Solaris as well as to increase the number of approved prescriptions for the drug.